CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Stamer, Ulrike M ^a,b   Zhang, Lan ^a,b   Book, Malte ^b   Lehmann, Lutz E ^b   Stuber, Frank ^b   Musshoff, Frank ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DIPYRONE; DRUG METABOLITE; NOROXYCODONE; NOROXYMORPHONE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PIRITRAMIDE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANESTHETIC RECOVERY; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG USE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; PATIENT SATISFACTION; PHARMACOGENETICS; POSTOPERATIVE ANALGESIA; POSTOPERATIVE CARE; POSTOPERATIVE PAIN; PROSPECTIVE STUDY;

AGED; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MORPHINANS; OXYCODONE; OXYMORPHONE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84875532794     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060239     Document Type: Article

References (44)

1. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH, (2010) Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 54: 232-240.
2. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, et al. (2010) Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 160: 919-930.
3. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, et al. (2011) Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig 31: 143-153.
4. Stamer UM, Lee EH, Rauers NI, Zhang L, Kleine-Brueggeney M, et al. (2011) CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg 113: 48-54.
5. Apfel CC, Kranke P, Katz MH, Goepfert C, Papenfuss T, et al. (2002) Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 88: 659-668.
6. AWMF-Leitlinien-Register Nr.041/001 (2012) S3-Leitlinie "Behandlung akuter perioperativer und posttraumatischer Schmerzen". Available: http://awmf.org. Accessed 2012.
7. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, et al. (2007) Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 82: 41-47.
8. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, et al. (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83: 234-242.
9. Naito T, Takashina Y, Yamamoto K, Tashiro M, Ohnishi K, et al. (2011) CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol 51: 1529-1538.
10. Wojnowski L, Kamdem LK, (2006) Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2: 171-182.
11. Musshoff F, Trafkowski J, Kuepper U, Madea B, (2006) An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites. J Mass Spectrom 41: 633-640.
12. Society of Toxicological and Forensic Chemistry (2012) Requirements for the validation of analytical methods. Available: http://gtfch.org/cms. Accessed 2011.
13. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, et al. (2009) The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 104: 335-344.
14. Bouillon T, Kietzmann D, Port R, Meineke I, Hoeft A, (1999) Population pharmacokinetics of piritramide in surgical patients. Anesthesiology 90: 7-15.
15. Kumar N, Rowbotham DJ, (1999) Piritramide. Br J Anaesth 82: 3-5.
16. NCBI SNP Database (2012). Available: http://ncbi.nlm.nih.gov/SNP. Accessed 2012.
17. Zhou SF, (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48: 689-723.
18. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, et al. (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79: 461-479.
19. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, et al. (2006) Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105: 801-812.
20. Peckham EM, Traynor JR, (2006) Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316: 1195-1201.
21. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, et al. (2004) Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther 308: 547-554.
22. Lemberg KK, Heiskanen TE, Neuvonen M, Kontinen VK, Neuvonen PJ, et al. (2010) Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients. Scandinavian Journal of Pain 1: 24-33.
23. Heiskanen T, Olkkola KT, Kalso E, (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64: 603-611.
24. Leow KP, Smith MT, (1994) The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 54: 1229-1236.
25. Weinstein SH, Gaylord JC, (1979) Determination of oxycodone in plasma and identification of a major metabolite. J Pharm Sci 68: 527-528.
26. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, et al. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74: 245-254.
27. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C, (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526.
28. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, et al. (2008) CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 30: 689-699.
29. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, et al. (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160: 907-918.
30. Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, et al. (2009) Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65: 263-271.
31. Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, et al. (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110: 1371-1378.
32. Saari TI, Gronlund J, Hagelberg NM, Neuvonen M, Laine K, et al. (2010) Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 66: 387-397.
33. Gronlund J, Saari T, Hagelberg N, Martikainen IK, Neuvonen PJ, et al. (2010) Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. J Clin Pharmacol 50: 101-108.
34. Kharasch ED, Vangveravong S, Buck N, London A, Kim T, et al. (2011) Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. Clin Pharmacol Ther 89: 562-570.
35. De Leon J, Dinsmore L, Wedlund P, (2003) Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 23: 420-421.
36. Foster A, Mobley E, Wang Z, (2007) Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract 7: 352-356.
37. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D, (1996) Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 12: 182-189.
38. Susce MT, Murray-Carmichael E, de LJ, (2006) Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 30: 1356-1358.
39. Stubhaug A, Grimstad J, Breivik H, (1995) Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Pain 62: 111-118.
40. Lemberg KK, Heiskanen TE, Kontinen VK, Kalso EA, (2009) Pharmacology of oxycodone: does it explain why oxycodone has become a bestselling strong opioid? Scandinavian Journal of Pain 1: S18-S23.
41. Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE, Raeder J, (2009) A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. Anesth Analg 109: 1279-1283.
42. Kalso E, (2007) How different is oxycodone from morphine? Pain 132: 227-228.
43. Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, et al. (1991) Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 35: 642-646.
44. Silvasti M, Rosenberg P, Seppala T, Svartling N, Pitkanen M, (1998) Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 42: 576-580.